Muchas gracias!

Kesimpta (ofatumumab) suele causar reacciones relacionadas con la inyección (fiebre, dolor de cabeza, escalofríos, fatiga) e infecciones de las vías respiratorias superiores. Estas generalmente aparecen dentro de las 24 horas posteriores a las primeras dosis y suelen disminuir con el tiempo. Si bien comienza a reducir las células B de inmediato, la eficacia clínica significativa en la reducción de las recaídas de EM generalmente es evaluada por un médico en un plazo de 3 a 6 meses.

Patient reviews for Kesimpta (ofatumumab) are mixed, with an average rating of 7.1 out of 10 on Drugs.com and 3.8 out of 5 on WebMD, reflecting a split between high efficacy and significant tolerability issues. 56% of reviewers reported a positive experience, citing stability in MRI results, reduced relapse frequency, and the convenience of monthly self-injection, while 17% reported negative experiences due to severe side effects.

Common positive feedback highlights that the medication has stopped further MS activity and improved quality of life for many, with users noting that side effects like headaches and fatigue often subside after the initial loading doses. Conversely, negative reviews frequently mention frequent infections, severe headaches, muscle spasms, and flu-like reactions, with some patients reporting worsening symptoms or hospitalization for conditions like pneumonia and meningitis.

While some patients describe Kesimpta as a "game changer" compared to previous treatments like Ocrevus or Tysabri, others express a love/hate relationship with the drug due to the trade-off between disease control and side effects such as mouth sores, hair loss, and immunocompromise. Overall, patient experiences vary significantly, with many emphasizing the need to discuss individual risk factors with a healthcare provider before starting treatment.

Cuáles son los efectos secundarios de Ofatumumab? Y, ¿después de cuántos meses de administrar Ofatumumab se puede saber si es efectivo o no con mi esclerosis múltiple?